Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ying-Chou Chen & Wei-Che Lin. (2017) Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures. Patient Preference and Adherence 11, pages 839-843.
Read now
Read now
Yuan-Hung Kuo, Chien-Hung Chen, Jing-Houng Wang, Chou-Hung Hung, Po-Lin Tseng, Sheng-Nan Lu, Chi-Sin Changchien & Chuan-Mo Lee. (2010) Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scandinavian Journal of Gastroenterology 45:1, pages 75-81.
Read now
Read now
Peter Revill & Stephen Locarnini. (2006) The Clinical Virology of Hepatitis B. Future Virology 1:3, pages 349-360.
Read now
Read now
Articles from other publishers (53)
Piotr Rzymski, Dorota Zarębska-Michaluk & Robert Flisiak. (2023) Could chronic HBV infection explain Beethoven's hearing loss? Implications for patients currently living with hepatitis B. Journal of Infection 87:3, pages 171-176.
Crossref
Crossref
Hsin-Wei Fang, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu & Chien-Hung Chen. (2023) Post-treatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment. Digestive and Liver Disease 55:9, pages 1223-1229.
Crossref
Crossref
Chien‐Hung Chen, Cheng‐Yuan Peng, Tsung‐Hui Hu, Jing‐Houng Wang, Chao‐Hung Hung & Sheng‐Nan Lu. (2023) Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics 58:3, pages 334-345.
Crossref
Crossref
Chien-Hung Chen, Wen-Juei Jeng, Tsung-Hui Hu, Yen-Chun Liu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu & Rong-Nan Chien. (2023) HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Digestive and Liver Disease 55:6, pages 771-777.
Crossref
Crossref
Kizito Eneye Bello, Tuan Nur Akmalina Mat Jusoh, Ahmad Adebayo Irekeola, Norhidayah Abu, Nur Amalin Zahirah Mohd Amin, Nazri Mustaffa & Rafidah Hanim Shueb. (2023) A Recent Prevalence of Hepatitis B Virus (HBV) Genotypes and Subtypes in Asia: A Systematic Review and Meta-Analysis. Healthcare 11:7, pages 1011.
Crossref
Crossref
Tzu-Ning Tseng, Wen-Juei Jeng, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu & Chien-Hung Chen. (2023) Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. Journal of Antimicrobial Chemotherapy 78:2, pages 436-439.
Crossref
Crossref
Shao-Ming Chiu, Kuo-Chin Chang, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu & Chien-Hung Chen. (2022) Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Digestive Diseases and Sciences 68:2, pages 665-675.
Crossref
Crossref
Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien & Pin-Nan Cheng. (2022) Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association 121:11, pages 2265-2272.
Crossref
Crossref
Chen-Hsuan Wu, Wei-Cheng Huang, Chien-Hung Chen & Sheng-Nan Lu. (2022) Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers. Biomedical Journal 45:5, pages 798-805.
Crossref
Crossref
Hsin-Wei Fang, Yi-Hao Yen, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu & Chien-Hung Chen. (2021) Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. Digestive Diseases and Sciences 67:7, pages 3402-3411.
Crossref
Crossref
Chien-Hung Chen, Cheng-Yuan Peng, Yuan-Hung Kuo, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang & Sheng-Nan Lu. (2022) Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen–Positive Patients. The Journal of Infectious Diseases 225:11, pages 1974-1981.
Crossref
Crossref
Tzu-Ning Tseng, Yuan-Hung Kuo, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu & Chien-Hung Chen. (2022) Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. Viruses 14:6, pages 1189.
Crossref
Crossref
Pao‐Yuan Huang, Jing‐Houng Wang, Chao‐Hung Hung, Sheng‐Nan Lu, Tsung‐Hui Hu & Chien‐Hung Chen. (2021) The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients. Journal of Viral Hepatitis 28:8, pages 1141-1149.
Crossref
Crossref
Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu & Chien-Hung Chen. (2021) Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatology International 15:2, pages 301-309.
Crossref
Crossref
Shao-Ming Chiu, Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu & Chien-Hung Chen. (2020) Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. Clinical Gastroenterology and Hepatology 18:13, pages 2989-2997.e3.
Crossref
Crossref
Tzu-Ning Tseng, Tsung-Hui Hu, Jing-Houng Wang, Yuan-Hung Kuo, Chao-Hung Hung, Sheng-Nan Lu, Wen-Juei Jeng & Chien-Hung Chen. (2020) Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clinical Gastroenterology and Hepatology 18:12, pages 2803-2812.e2.
Crossref
Crossref
Katherine E. Squires, Douglas L. Mayers, Gregory R. Bluemling, Alexander A. Kolykhalov, David B. Guthrie, Prabhakar Reddy, Debbie G. Mitchell, Manohar T. Saindane, Zachary M. Sticher, Vindhya Edpuganti & Abel De La Rosa. (2020) ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrobial Agents and Chemotherapy 64:9.
Crossref
Crossref
Fai-Meng Sou, Tsung-Hui Hu, Chao-Hung Hung, Hsueh-Chou Lai, Jing-Houng Wang, Sheng-Nan Lu, Cheng-Yuan Peng & Chien-Hung Chen. (2020) Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatology International 14:4, pages 513-520.
Crossref
Crossref
Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Hsueh-Chou Lai, Chao-Hung Hung, Sheng-Nan Lu & Cheng-Yuan Peng. (2019) Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatology International 14:3, pages 317-325.
Crossref
Crossref
Te-Ling Ma, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu & Chien-Hung Chen. (2019) Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLOS ONE 14:10, pages e0222221.
Crossref
Crossref
Yi-Hsing Chen, Sheng-Nan Lu, Jing-Hung Wang, Chao-Hung Hung, Tsung-Hui Hu & Chien-Hung Chen. (2019) Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Digestive Diseases and Sciences 64:9, pages 2563-2569.
Crossref
Crossref
Chien-Hung Chen, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu, Hsueh-Chou Lai, Tsung-Hui Hu, Chia-Hsin Lin & Cheng-Yuan Peng. (2019) The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. The Journal of Infectious Diseases 219:10, pages 1624-1633.
Crossref
Crossref
Ming‐Te Kuo, Tsung‐Hui Hu, Chao‐Hung Hung, Jing‐Houng Wang, Sheng‐Nan Lu, Kai‐Lung Tsai & Chien‐Hung Chen. (2018) Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Alimentary Pharmacology & Therapeutics 49:2, pages 218-228.
Crossref
Crossref
Hung‐Hsien Chiang, Chuan‐Mo Lee, Tsung‐Hui Hu, Chao‐Hung Hung, Jing‐Houng Wang, Sheng‐Nan Lu, Hsueh‐Chou Lai, Wen‐Pang Su, Chia‐Hsin Lin, Cheng‐Yuan Peng & Chien‐Hung Chen. (2018)
A combination of the on‐treatment
FIB
‐4 and alpha‐foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir
. Liver International 38:11, pages 1997-2005.
Crossref
Crossref
C.-H. Chen, C.-H. Hung, J.-H. Wang, S.-N. Lu, T.-H. Hu & C.-M. Lee. (2018) Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clinical Microbiology and Infection 24:9, pages 997-1003.
Crossref
Crossref
C.‐H. Chen, Y.‐C. Hsu, S.‐N. Lu, C.‐H. Hung, J.‐H. Wang, C.‐M. Lee & T.‐H. Hu. (2018)
The incidence and predictors of
HBV
relapse after cessation of tenofovir therapy in chronic hepatitis B patients
. Journal of Viral Hepatitis 25:5, pages 590-597.
Crossref
Crossref
C.‐H. Hung, J.‐H. Wang, S.‐N. Lu, T.‐H. Hu, C.‐M. Lee & C.‐H. Chen. (2017) Hepatitis B surface antigen loss and clinical outcomes between HBeAg‐negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. Journal of Viral Hepatitis 24:7, pages 599-607.
Crossref
Crossref
Hsin‐Ming Wang, Chao‐Hung Hung, Chuan‐Mo Lee, Sheng‐Nan Lu, Jing‐Houng Wang, Yi‐Hao Yen, Kwong‐Ming Kee, Kuo‐Chin Chang, Po‐Lin Tseng, Tsung‐Hui Hu & Chien‐Hung Chen. (2016) Three‐year efficacy and safety of tenofovir in nucleos(t)ide analog‐naïve and nucleos(t)ide analog‐experienced chronic hepatitis B patients. Journal of Gastroenterology and Hepatology 31:7, pages 1307-1314.
Crossref
Crossref
Ying‐Chou Chen, Fu‐Mei Su, Tien‐Tsai Cheng, Han‐Ming Lai & Shan‐Fu Yu. (2015) Is Long‐Term Anti‐Osteoporotic Treatment Associated with Greater Risk of Cancer in People with Severe Vertebral Fractures? A Hospital‐Based Cohort Study. Journal of the American Geriatrics Society 63:11, pages 2418-2419.
Crossref
Crossref
Chien-Hung Chen, Chao-Hung Hung, Tsung-Hui Hu, Jing-Houng Wang, Sheng-Nan Lu, Pei-Fang Su & Chuan-Mo Lee. (2015) Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology 13:11, pages 1984-1992.e1.
Crossref
Crossref
Chih‐Chien Yao, Chuan‐Mo Lee, Chao‐Hung Hung, Jing‐Houng Wang, Tsung‐Hui Hu, Sheng‐Nan Lu, Chi‐Sin Changchien, Mei‐Chin Hsu & Chien‐Hung Chen. (2015)
Combining age and
HBsAg
level predicts post‐treatment durability of nucleos(t)ide analogue‐induced
HBeAg
seroconversion
. Journal of Gastroenterology and Hepatology 30:5, pages 918-924.
Crossref
Crossref
Yoshihiko Yano. (2015) Hepatitis B virus infection in Indonesia. World Journal of Gastroenterology 21:38, pages 10714.
Crossref
Crossref
Chien-Hung Chen, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Chi-Sin Changchien & Chuan-Mo Lee. (2014) The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. Journal of Hepatology 61:3, pages 515-522.
Crossref
Crossref
Chien‐Hung Chen, Tsung‐Hui Hu, Chao‐Hung Hung, Jing‐Houng Wang, Sheng‐Nan Lu & Chuan‐Mo Lee. (2014)
Antiviral effect of entecavir in nucleos(t)ide analogue‐naïve and nucleos(t)ide analogue‐experienced chronic hepatitis
B
patients without virological response at week 24 or 48 of therapy
. Journal of Viral Hepatitis 21:8.
Crossref
Crossref
Chien-Hung Chen, Chih-Lang Lin, Tsung-Hui Hu, Chao-Hung Hung, Po-Lin Tseng, Jing-Houng Wang, Juan-Yu Chang, Sheng-Nan Lu, Rong-Nan Chien & Chuan-Mo Lee. (2014) Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. Journal of Hepatology 60:6, pages 1127-1134.
Crossref
Crossref
Tsung-Hui Hu, Ming-Chao Tsai, Yu-Shu Chien, Yen-Ta Chen, Te-Chuan Chen, Ming-Tzung Lin, Kuo-Chin Chang & King-Wah Chiu. (2012) A Novel Experience of Antiviral Therapy for Chronic Hepatitis B in Renal Transplant Recipients. Antiviral Therapy 17:4, pages 745-753.
Crossref
Crossref
Chien-Hung Chen, Jing-Houng Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chao-Hung Hung, Min-Hui Chang, Chi-Sin Changchien & Chuan-Mo Lee. (2012) Treatment Response and Evolution of HBV Resistance during Lamivudine plus Adefovir or Entecavir Therapy in Patients with Adefovir-Resistant Mutants. Antiviral Therapy 17:4, pages 701-709.
Crossref
Crossref
Chao-Hung Hung, Chien-Hung Chen, Sheng-Nan Lu, Jing-Houng Wang, Tsung-Hui Hu, Chao-Min Huang, Ming-Chao Tsai & Chuan-Mo Lee. (2012) Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. Antiviral Research 93:1, pages 55-63.
Crossref
Crossref
José Antonio Mata Marín, Carla Ileana Arroyo Anduiza, Gloría Mara Calderón, Sergio Cazares Rodríguez, José Luis Fuentes Allen, Rafael Arias Flores & Jesús Gaytán Martínez. (2012) Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico. Annals of Hepatology 11:1, pages 47-51.
Crossref
Crossref
Nedzad Music & Carl A. Gagnon. (2010) The role of porcine reproductive and respiratory syndrome (PRRS) virus structural and non-structural proteins in virus pathogenesis. Animal Health Research Reviews 11:02, pages 135-163.
Crossref
Crossref
Fuat Kurbanov, Yasuhito Tanaka & Masashi Mizokami. (2010) Geographical and genetic diversity of the human hepatitis B virus. Hepatology Research 40:1, pages 14-30.
Crossref
Crossref
Chien‐Hung Chen, Chi‐Sin Changchien, Chuan‐Mo Lee, Wei‐Chih Tung, Chao‐Hung Hung, Tsung‐Hui Hu, Jing‐Houng Wang, Jyh‐Chwan Wang & Sheng‐Nan Lu. (2009) A study on sequence variations in pre‐S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non‐B, non‐C hepatocellular carcinoma patients in Taiwan. International Journal of Cancer 125:3, pages 621-629.
Crossref
Crossref
Brian J. McMahon. (2008) The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatology International 3:2, pages 334-342.
Crossref
Crossref
Chien–Hung Chen, Chao–Hung Hung, Chuan–Mo Lee, Tsung–Hui Hu, Jing–Houng Wang, Jyh–Chwan Wang, Sheng–Nan Lu & Chi–Sin Changchien. (2007) Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients. Gastroenterology 133:5, pages 1466-1474.
Crossref
Crossref
Chien‐Hung Chen, Chuan‐Mo Lee, Chao‐Hung Hung, Tsung‐Hui Hu, Jing‐Houng Wang, Jyh‐Chwan Wang, Sheng‐Nan Lu & Chi‐Sin Changchien. (2007) Clinical significance and evolution of core promoter and precore mutations in HBeAg‐positive patients with HBV genotype B and C: a longitudinal study. Liver International 27:6, pages 806-815.
Crossref
Crossref
K. Luo, H. He, Z. Liu, Y. Zhu, Q. Mao & W. Liang. (2007) No significant differences in histology and response to interferon treatment in hepatitis B carriers of genotypes C and recombinant B. Journal of Viral Hepatitis 14:6, pages 419-425.
Crossref
Crossref
Qiaoxia Tong, Yanyan Wu & Duande Luo. (2007) Distribution of hepatitis B virus genotypes and its clinical significance in Hubei province, China. Journal of Huazhong University of Science and Technology 27:3, pages 274-277.
Crossref
Crossref
Chun‐Jen Liu, Pei‐Jer Chen, Ming‐Yang Lai, Feng‐Yi Lin, Tzusan Wang, Jia‐Horng Kao & Ding‐Shinn Chen. (2006) Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver International 26:8, pages 949-955.
Crossref
Crossref
N. Tran, R. Berne, R. Chann, M. Gauthier, D. Martin, M.-A. Armand, A. Ollivet, C. G. Teo, S. Ijaz, D. Flichman, M. Brunetto, K. P. Bielawski, C. Pichoud, F. Zoulim & G. Vernet. (2006) European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes. Journal of Clinical Microbiology 44:8, pages 2792-2800.
Crossref
Crossref
Nathalie Ganne-Carrié, Virginie Williams, Halima Kaddouri, Jean-Claude Trinchet, Samira Dziri-Mendil, Chakib Alloui, Nasser Al Hawajri, Paul Dény, Michel Beaugrand & Emmanuel Gordien. (2006) Significance of hepatitis B virus genotypes A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis District of Paris (France). Journal of Medical Virology 78:3, pages 335-340.
Crossref
Crossref
Chien-Hung Chen, Chuan-Mo Lee, Sheng-Nan Lu, Chi-Sin Changchien, Jyh-Chwan Wang, Jing-Houng Wang, Chao-Hung Hung & Tsung-Hui Hu. (2006) Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. Journal of Hepatology 44:1, pages 76-82.
Crossref
Crossref
Chun‐Jen Liu, Jia‐Horng Kao & Ding‐Shinn Chen. (2005) Therapeutic implications of hepatitis B virus genotypes. Liver International 25:6, pages 1097-1107.
Crossref
Crossref
Toumy Guettouche & H James Hnatyszyn. (2005) Chronic Hepatitis B and Viral Genotype: The Clinical Significance of Determining HBV Genotypes. Antiviral Therapy 10:5, pages 593-604.
Crossref
Crossref